Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348559 | 0.87 | DPP4 (0.53) | TLR2TLR1MDM2KMT2AITGB3 | |
| SCHEMBL13260142 | 0.85 | TLR2 (0.46) | TLR2TLR1MDM2KMT2AITGB3 | |
| SCHEMBL3723779 | 0.85 | TLR2 (0.46) | TLR2TLR1MDM2KMT2AITGB3 | |
| SCHEMBL2854141 | 0.83 | TLR2 (0.53) | TLR2TLR1MDM2KMT2AITGB3 | |
| SCHEMBL2854140 | 0.83 | TLR2 (0.53) | TLR2TLR1MDM2KMT2AITGB3 | |
| SCHEMBL2267346 | 0.82 | KMT2A (0.58) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL29362262 | 0.82 | KMT2A (0.58) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL12040103 | 0.82 | KMT2A (0.58) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL30885878 | 0.82 | KMT2A (0.58) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL29401707 | 0.82 | KMT2A (0.58) | TLR2TLR1MDM2KMT2AKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7144886-B2 | Dipeptidyl peptidase IV (DP-IV) inhibitors as anti-diabetic agents | FERRING B.V. (NL) | 2006-12-05 | — | — | US | disclosed |
| US-7125863-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2006-10-24 | — | — | US | disclosed |
| EP-1693365-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2006-08-23 | — | — | EP | disclosed |
| US-20050004205-A1 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents | FERRING B.V. (NL) | 2005-01-06 | — | — | US | disclosed |
| EP-1280797-B1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING BV (NL) | 2004-10-13 | — | — | EP | disclosed |
| US-20040082497-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2004-04-29 | — | — | US | disclosed |
| US-20030216450-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216450-A1 | Inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP8 | TLR2 3976/4885TLR1 3500/4885MDM2 4279/4885 |
| US-20040082497-A1 | Inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP3 | TLR2 4376/4885TLR1 2301/4885MDM2 1982/4885 |
| US-20050004205-A1 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents | DPP4, DPP8, DPP3 | TLR2 3203/4885TLR1 3914/4885MDM2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.